menu
    • menu
    [{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"HVMN Inc | KETONE-IQ","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"1,3 Butanediol","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ","highestDevelopmentStatusID":"7","companyTruncated":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"HVMN Inc | KETONE-IQ","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"1,3 Butanediol","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ","highestDevelopmentStatusID":"7","companyTruncated":"Johns Hopkins University \/ HVMN Inc | KETONE-IQ"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD313","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Apnimed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SAS0421a","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Apnimed","highestDevelopmentStatusID":"7","companyTruncated":"Brigham and Women's Hospital \/ Apnimed"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZLT-101","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zelira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10506","moa":"Unknown","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hansoh Pharma \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Johns Hopkins University

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Johns Hopkins University

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 1,3 Butanediol

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : HVMN Inc | KETONE-IQ

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Exogenous Ketones on Sleep Apnea

                            Details : 1,3 Butanediol is a Dietary Supplement drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Apnea, Obstructive.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 13, 2024

                            Lead Product(s) : 1,3 Butanediol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : HVMN Inc | KETONE-IQ

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hansoh Pharma

                            China arrow
                            Florida Innovation
                            Not Confirmed

                            Hansoh Pharma

                            China arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-10506

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase â… b/â…¡ Study of HS-10506 in Chinese Participants With Insomnia Disorder

                            Details : HS-10506 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 28, 2024

                            Lead Product(s) : HS-10506

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apnimed

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Apnimed

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AD313

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

                            Details : AD313 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Apnea, Obstructive.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 01, 2021

                            Lead Product(s) : AD313

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zelira Therapeutics

                            Australia arrow
                            Florida Innovation
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZLT-101

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

                            Details : 23 chronic insomnia patients treated with ZLT-101, Zelira's proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2020

                            Lead Product(s) : ZLT-101

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Brigham and Women's Hospital

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Brigham and Women's Hospital

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAS0421a

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : Apnimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

                            Details : SAS0421a is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sleep Apnea Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 27, 2019

                            Lead Product(s) : SAS0421a

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Apnimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth